XML 28 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Ideal BioStent (Details Textual) (USD $)
12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Nov. 30, 2011
Nov. 30, 2012
Foreclosure Sale Agreement [Member]
Dec. 31, 2010
Foreclosure Sale Agreement [Member]
Nov. 15, 2010
Foreclosure Sale Agreement [Member]
Oct. 12, 2010
Foreclosure Sale Agreement [Member]
Sep. 30, 2010
Foreclosure Sale Agreement [Member]
Milestones One [Member]
Sep. 30, 2010
Foreclosure Sale Agreement [Member]
Milestones Two [Member]
Sep. 30, 2010
Foreclosure Sale Agreement [Member]
Milestones Three [Member]
Mar. 31, 2011
Rutgers License Agreement [Member]
Sep. 30, 2010
Rutgers License Agreement [Member]
Nov. 30, 2012
Rutgers License Agreement [Member]
Sep. 30, 2010
Rutgers License Agreement [Member]
Third Anniversary [Member]
Sep. 30, 2010
Rutgers License Agreement [Member]
Fourth Anniversary [Member]
Nov. 30, 2012
Initiation of First in Human Clinical Trials [Member]
Nov. 30, 2012
Initiation of Pivotal Human Clinical Trials [Member]
Nov. 30, 2012
Submission of Application for Market Approval [Member]
Asset Acquisition, Cost of Acquired Assets, Cash Paid $ 400,000   $ 130,000 $ 135,000 $ 135,000                      
Cash Payments to Sellers, Milestone Criteria           3,000,000 5,000,000 5,000,000                
Accounts Payable           300,000 1,000,000 3,000,000                
Potential Payment for Failure to Achieve Milestone   4,300,000                            
License Costs                   50,000            
Maintenance Costs                       25,000 50,000      
License Agreement, Unpaid Costs                   136,000            
Payments for License Costs                 $ 135,000              
Future Royalties, Milestone Payments, Description                           $50,000 is payable upon initiation of first in-human clinical trials anywhere in the world. $200,000 is payable upon initiation of pivotal human clinical trials anywhere in the world in connection with submitting an application for market approval to a regulatory authority; $300,000 is payable upon submission of an application for market approval to a regulatory authority anywhere in the world.
Offset against future royalty payments earned                     50% of the Rutgers milestone payments